Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Kalorama Reports | Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition

It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.

Several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis. In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:

* Melonoma Vaccines

* Lung Cancer Vaccines

* Prostate Cancer Vaccines

* Cervical Cancer Vaccines

* Brain Cancer Vaccines

* Colon/Rectal Cancer Vaccines

* Breast Cancer Vaccines

* Lymphoma Vaccines

* Ovarian Cancer Vaccines

* Leukemia Vaccines

* Bladder Cancer Vaccines

As part of its exhaustive research and analysis, this report provides:

* Forecasts for Future Revenues from Cancer Vaccines

* Cancer Epidemiology

* Reviews of Products in the Pipeline

* Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market

* Directory of Related Companies

Some of the issues discussed in this report important for anyone operating in this market include:

* Introduction

* Early Detection and Screening

* Monoclonal Antibodies and Therapeutic Vaccines

* Political and Social Pressure

* Insurance and Reimbursement Issues

* Personalized Medicine

* Pharmacogenomics

* Vaccine Strategies

* New Genetic Technique

* Future Growth in Vaccines

As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:

* Antigenics, Inc.

* Avax Technologies, Inc.

* Biovest International, Inc.

* Cell Genesys, Inc.

* Dendreon Corporation

* Genitope Corporation

* GlaxoSmithKline plc

* Merck & Company, Inc.

* Northwest Biotherapeutics, Inc.

* NovaRx

* Oncothyreon

* Vaccinogen

* Vical, Inc.

Nov 1, 2008

250 Pages - Pub ID: KLI1646591
Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions